AN2 Therapeutics, Inc. (ANTX) is an innovative biopharmaceutical company with a focus on developing and commercializing novel therapies for patients suffering from rare, orphan, and unmet need diseases. As a pioneering entity in the medical and biotechnology field, the company is spearheading cutting-edge research and clinical programs to improve the lives of patients around the world.
ANTX provides a unique blend of innovation and dedication in its quest to tackle the most challenging medical conditions. Their mission is driven by a desire to alleviate suffering and potentially offer cures where there are currently limited or no treatment options. Each research and development endeavor they undertake is personalized to target specific diseases and to produce solutions that aim at bettering patient outcomes.
The company's leading product candidate is ANT-1207, an inhaled, lipid-complexed formulation of amikacin for the treatment of Nontuberculous Mycobacteria (NTM) lung disease. This is a progressive and chronic condition that can result in severe lung damage, and for which there is an urgent need for new treatment options. By formulating amikacin, a well-established antibiotic, in a way that can be inhaled directly into the lungs, ANTX hopes to offer a powerful new tool for treating NTM lung disease.
In addition to its clinical programs, AN2 Therapeutics, Inc. stands out for its practices of integrating collaboration, fostering talent, and building strong partnerships at the core of its business activities. The company sets itself apart by maintaining strong relationships with healthcare professionals, researchers, and patients, and it places a foundation of trust and value in its partnership networks that extends to every operation.
As a contributor to the advancement of global healthcare, ANTX envisions itself as a leader in disease management and healthcare solutions, hence the active involvement in the field of research and development of novel therapeutics.
There's a relentless pursuit of excellence in everything they do, underlining their commitment to patient care and scientific advancement in the biotechnological field. This marks ANTX as not just a company, but a team of professionals dedicated to transforming people’s lives and seeking new ways to fight some of the world’s most serious diseases.
In summary, AN2 Therapeutics, Inc. (ANTX) is a patient-centric, research-intensive biopharmaceutical company with a mission to advance healthcare and bring new hope to patients battling rare and life-threatening diseases.
Income statement
Balance sheet statement
Cash flow statement
Current assets / Current liabilities
Equity / Debt / Cash
Dividends
AN2 Therapeutics Director Patricia A. Martin acquired 389 shares of AN2 Therapeutics, Inc. common stock at no cost on October 12, 2026. These shares were issued as compensation in lieu of cash under the company's non-employee director compensation plan and vested immediately. Following this transaction, Martin's direct beneficial ownership in the company increased to 19,252 shares.
Director Kabeer Aziz acquired 2,465 shares of AN2 Therapeutics, Inc. (NASDAQ:ANTX) common stock on October 12, 2026, at no cost, as part of the company's non-employee director compensation program. These shares vested immediately and increased his direct holdings to 61,571, with additional indirect holdings through two Adjuvant funds totaling 2,373,500 shares. The transaction was reported in a Form 4 filing with the SEC on October 13, 2026.
AN2 Therapeutics has received extended funding from the Gates Foundation for its collaboration with GSK to research and develop boron-based leucyl-tRNA synthetase (LeuRS) inhibitors for tuberculosis. This additional funding will support the application of AN2's boron chemistry platform to discover new small-molecule therapeutics for tuberculosis, a leading cause of death from infectious disease. The collaboration aims to advance innovative approaches for new treatment options, building on the clinical validation of LeuRS as a therapeutic target.
AN2 Therapeutics (NASDAQ:ANTX) has secured an extension of funding from the Gates Foundation for its ongoing tuberculosis research collaboration with GSK. This funding will support continued development of boron-based leucyl-tRNA synthetase inhibitors as potential treatments for TB, leveraging AN2's boron chemistry platform. The collaboration aims to advance new small molecule therapeutics for infectious diseases.